文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

mRNA 疫苗加强针接种后对 COVID-19 免疫反应的持久性。

Durability of immune responses to mRNA booster vaccination against COVID-19.

机构信息

Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, California, USA.

Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Atlanta, Georgia, USA.

出版信息

J Clin Invest. 2023 May 15;133(10):e167955. doi: 10.1172/JCI167955.


DOI:10.1172/JCI167955
PMID:36951954
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10178835/
Abstract

BackgroundMaintaining durable immunity following vaccination represents a major challenge, but whether mRNA booster vaccination improves durability is unknown.MethodsWe measured antibody responses in 55 healthy adults, who received a booster dose of the Pfizer-BioNTech or Moderna vaccine against SARS-CoV-2 and calculated the half-life of the antibody titers. We also measured memory B and T cell responses in a subset of 28 participants. In 13 volunteers who received a second booster vaccine, we measured serum antibody titers and memory B and T cell responses.ResultsThe booster (third immunization) dose at 6 to 10 months increased the half-life of the serum-neutralizing antibody (nAb) titers to 76 days from 56 to 66 days after the primary 2-dose vaccination. A second booster dose (fourth immunization) a year after the primary vaccination further increased the half-life to 88 days. However, despite this modestly improved durability in nAb responses against the ancestral (WA.1) strain, there was a loss of neutralization capacity against the Omicron subvariants BA.2.75.2, BQ.1.1, and XBB.1.5 (48-, 71-, and 66-fold drop in titers, respectively, relative to the WA.1 strain). Although only 45% to 65% of participants demonstrated a detectable nAb titer against the newer variants after the booster (third dose), the response declined to below the detection limit in almost all individuals by 6 months. In contrast, booster vaccination induced antigen-specific memory B and T cells that persisted for at least 6 months.ConclusionThe durability of serum antibody responses improves only marginally following booster immunizations with the Pfizer-BioNTech or Moderna mRNA vaccines.

摘要

背景:在接种疫苗后保持持久的免疫力是一项重大挑战,但 mRNA 加强针接种是否能提高持久性尚不清楚。

方法:我们测量了 55 名健康成年人接种辉瑞-生物科技或 Moderna 公司的 SARS-CoV-2 疫苗加强针后的抗体反应,并计算了抗体滴度的半衰期。我们还在 28 名参与者中测量了记忆 B 和 T 细胞反应。在 13 名接受第二次加强疫苗的志愿者中,我们测量了血清抗体滴度和记忆 B 和 T 细胞反应。

结果:在 6 至 10 个月时,加强针(第三次接种)将血清中和抗体(nAb)滴度的半衰期从两剂疫苗接种后 56 天延长至 76 天。在初次接种一年后进行第二次加强针(第四次接种)进一步将半衰期延长至 88 天。然而,尽管 nAb 对原始(WA.1)株的反应持久性略有提高,但对奥密克戎亚变体 BA.2.75.2、BQ.1.1 和 XBB.1.5 的中和能力丧失。与 WA.1 株相比,nAb 滴度分别下降了 48、71 和 66 倍。尽管在加强针(第三剂)后只有 45%至 65%的参与者对新变体有可检测到的 nAb 滴度,但在几乎所有个体中,反应在 6 个月内下降到检测限以下。相比之下,加强针接种诱导了抗原特异性记忆 B 和 T 细胞,这些细胞至少持续了 6 个月。

结论:辉瑞-生物科技或 Moderna mRNA 疫苗加强针接种后,血清抗体反应的持久性仅略有提高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2702/10178835/940646c243e4/jci-133-167955-g143.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2702/10178835/dddb58712a5d/jci-133-167955-g140.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2702/10178835/82674b478bf7/jci-133-167955-g141.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2702/10178835/97cb56988d26/jci-133-167955-g142.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2702/10178835/940646c243e4/jci-133-167955-g143.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2702/10178835/dddb58712a5d/jci-133-167955-g140.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2702/10178835/82674b478bf7/jci-133-167955-g141.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2702/10178835/97cb56988d26/jci-133-167955-g142.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2702/10178835/940646c243e4/jci-133-167955-g143.jpg

相似文献

[1]
Durability of immune responses to mRNA booster vaccination against COVID-19.

J Clin Invest. 2023-5-15

[2]
Durability of immune responses to the booster mRNA vaccination against COVID-19.

medRxiv. 2022-12-4

[3]
Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals.

Microbiol Spectr. 2023-8-17

[4]
COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.

Vaccine. 2023-8-14

[5]
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.

J Clin Oncol. 2022-11-20

[6]
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.

J Infect. 2024-10

[7]
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.

Lancet Infect Dis. 2024-4

[8]
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.

Microbiol Spectr. 2024-10-3

[9]
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.

J Infect. 2023-9

[10]
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.

Front Immunol. 2023

引用本文的文献

[1]
Adjuvanted Protein Vaccines Boost RNA-Based Vaccines for Broader and More Potent Immune Responses.

Vaccines (Basel). 2025-7-28

[2]
Challenges and opportunities in mRNA vaccine development against bacteria.

Nat Microbiol. 2025-8

[3]
Teaching an old vector new tricks: the surprising versatility of AAV vaccines.

J Virol. 2025-8-19

[4]
Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters.

J Transl Med. 2025-7-11

[5]
Antibody Kinetics of Immunological Memory in SARS-CoV-2-Vaccinated Healthcare Workers-The ORCHESTRA Project.

Vaccines (Basel). 2025-6-5

[6]
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection.

Commun Med (Lond). 2025-6-20

[7]
Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year.

Viruses. 2025-4-29

[8]
Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.

Hum Vaccin Immunother. 2025-12

[9]
Intestinal Microbiota and Vaccinations: A Systematic Review of the Literature.

Vaccines (Basel). 2025-3-12

[10]
Ionizable lipid nanoparticles of mRNA vaccines elicit NF-κB and IRF responses through toll-like receptor 4.

NPJ Vaccines. 2025-4-17

本文引用的文献

[1]
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster.

N Engl J Med. 2023-1-12

[2]
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.

Cell Host Microbe. 2023-1-11

[3]
Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273.

Ann Allergy Asthma Immunol. 2023-1

[4]
Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.

JAMA Netw Open. 2022-9-1

[5]
Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa.

N Engl J Med. 2022-10-6

[6]
Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.

N Engl J Med. 2022-9-29

[7]
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.

N Engl J Med. 2022-10-6

[8]
Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine.

Sci Transl Med. 2022-8-17

[9]
Durability of immune responses to the BNT162b2 mRNA vaccine.

Med. 2022-1-14

[10]
Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose.

Nat Immunol. 2022-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索